Blood
Articles in this Issue
Efficacy and safety of daratumumab in intermediate/high-risk smoldering multiple myeloma: final analysis of CENTAURUS
Abstract Early intervention in smoldering multiple myeloma (SMM) may delay progression to MM. Here, we present the final analysis of the phase 2 CENTAURUS study. In total, 123 patien...
Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial
Abstract Patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) have poor outcomes (complete response [CR] rates with standard salvage therapy gemcitabine p...
Daratumumab: a game changer in early myeloma
Appearances deceive: unmasking mantle cell lymphoma with prolymphocytic morphology
Zhu H-H, Hu J, Lo-Coco F, Jin J. The simpler, the better: oral arsenic for acute promyelocytic leukemia. <i>Blood</i>. 2019;134(7):597-605.
Targeting cell-surface VISTA expression on allospecific naïve T cells promotes tolerance
Abstract The success of allogeneic hematopoietic stem cell transplantation (allo-HSCT) can be limited by graft-versus-host disease (GVHD). T-cell activation is a key factor in GVHD p...
Paraspinal mass and lower extremity weakness in a patient with thalassemia
Tumor burden quantified by soluble B-cell maturation antigen and metabolic tumor volume determines myeloma CAR-T outcomes
Abstract Chimeric antigen receptor T-cell (CAR-T) therapy has emerged as a breakthrough treatment for relapsed and refractory multiple myeloma (RRMM). However, these products are com...
CD3×CD20 bispecifics + chemotherapy: good news for R/R DLBCL
SMAC mimetics in action in chronic myeloid leukemia
The United Kingdom Infected Blood Inquiry: its findings and lessons for the future of transfusion
Abstract The UK Infected Blood Inquiry report was published in May 2024 after 6 years of taking oral and written evidence from patients, clinicians, blood services, government offici...
IL-1R1 and IL-18 signals regulate mesenchymal stromal cells in an aged murine model of myelodysplastic syndromes
Abstract Myelodysplastic syndromes (MDS) are age-related diseases characterized by bone marrow (BM) dysfunction and an increased risk for developing acute leukemia. Although there is...
sBCMA and MTV prediction of outcome for CART
Targeting IL-1/IL-18 mitigates MDS in aged mice
High-throughput drug screening identifies SMAC mimetics as enhancers of NK-cell cytotoxicity in chronic myeloid leukemia
Abstract Natural killer (NK) cells have proven to be safe and effective immunotherapies, associated with favorable treatment responses in chronic myeloid leukemia (CML). Augmenting N...
Hitting the bullseye in GVHD
How I manage patients with unexplained cytopenia
Abstract The term “unexplained cytopenia” is used to describe a condition characterized by peripheral blood cytopenia that cannot be attributed to identifiable causes using conventio...